Investments
208Portfolio Exits
73About HBM Healthcare Investments
HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
Want to inform investors similar to HBM Healthcare Investments about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest HBM Healthcare Investments News
Aug 25, 2023
Fore Biotherapeutics , a Philadelphia, PA-based precision oncology company, raised $75M in Series D funding. The round was led by SR One and Medicxi, with participation from existing investors OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management and Samsung Securities. In connection with the financing, Giovanni Mariggi, Partner at Medicxi, has joined FORE Biotherapeutics’ Board of Directors. Fore Biotherapeutics is a precision oncology company dedicated to developing plixorafenib, a Class 1/V600 and 2 BRAF inhibitor with demonstrated clinical safety and early efficacy signals in the previous Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without adequate treatment options. The company intends to use the funds to accelerate the clinical development of plixorafenib, its novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. In addition, Matthew E. Ros will step down as CEO and member of the Board of Directors; Shawn M. Leland, PharmD, RPh, advisor to SR One and former Founder, President, and CEO of Elevation Oncology, appointed interim CEO and member of the Board of Directors. FinSMEs 12/08/2023
HBM Healthcare Investments Investments
208 Investments
HBM Healthcare Investments has made 208 investments. Their latest investment was in FORE Biotherapeutics as part of their Series D on August 8, 2023.
HBM Healthcare Investments Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/22/2023 | Series D | FORE Biotherapeutics | $75M | No | 2 | |
8/9/2023 | Series C | ADARx Pharmaceuticals | $200M | Yes | Ascenta Capital, Bain Capital Life Sciences, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, TCG Crossover, Venrock Healthcare Capital Partners, and Vivo Capital | 1 |
8/7/2023 | PIPE - II | IO Biotech | $75M | No | Altamont Pharmaceutical Holdings, Armistice Capital, HBM Healthcare Investments, Kurma Partners, Logos Capital, Lundbeckfond Ventures, Marshall Wace Asset Management, Novo Holdings, PFM Health Sciences, Pivotal Life Sciences, Red Hook Management, Samsara BioCapital, Stonepine Capital Management, Sunstone Capital, Undisclosed Investors, and Vivo Capital | 2 |
7/27/2023 | Series A - II | |||||
6/8/2023 | Series B |
Date | 8/22/2023 | 8/9/2023 | 8/7/2023 | 7/27/2023 | 6/8/2023 |
|---|---|---|---|---|---|
Round | Series D | Series C | PIPE - II | Series A - II | Series B |
Company | FORE Biotherapeutics | ADARx Pharmaceuticals | IO Biotech | ||
Amount | $75M | $200M | $75M | ||
New? | No | Yes | No | ||
Co-Investors | Ascenta Capital, Bain Capital Life Sciences, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, TCG Crossover, Venrock Healthcare Capital Partners, and Vivo Capital | Altamont Pharmaceutical Holdings, Armistice Capital, HBM Healthcare Investments, Kurma Partners, Logos Capital, Lundbeckfond Ventures, Marshall Wace Asset Management, Novo Holdings, PFM Health Sciences, Pivotal Life Sciences, Red Hook Management, Samsara BioCapital, Stonepine Capital Management, Sunstone Capital, Undisclosed Investors, and Vivo Capital | |||
Sources | 2 | 1 | 2 |
HBM Healthcare Investments Portfolio Exits
73 Portfolio Exits
HBM Healthcare Investments has 73 portfolio exits. Their latest portfolio exit was Mineralys Therapeutics on February 10, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
2/10/2023 | IPO | Public | 5 | ||
12/14/2022 | Acquired | 2 | |||
11/15/2022 | IPO | Public | 3 | ||
Date | 2/10/2023 | 12/14/2022 | 11/15/2022 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 5 | 2 | 3 |
HBM Healthcare Investments Team
2 Team Members
HBM Healthcare Investments has 2 team members, including current Chief Executive Officer, Andreas Wicki.
Name | Work History | Title | Status |
|---|---|---|---|
Andreas Wicki | Chief Executive Officer | Current | |
Name | Andreas Wicki | |
|---|---|---|
Work History | ||
Title | Chief Executive Officer | |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
